AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most
diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practise of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
At Bristol Myers Squibb, we are inspired by a single vision-transforming patients’ lives through science. Over the last several decades, our innovative medicines have improved how cancer is treated, making long-term survival a possibility for more patients. Across a broad range of solid tumours and blood disorders, we strive to help more patients with our medicines, scientific discovery and investigational research.Our scientists are exploring new frontiers in the future of personalised medicine, and through new digital platforms, we are converting decades of research and data into insights that sharpen the focus of our work. The breadth of our portfolio, deep scientific expertise, cutting-edge capabilities, and discovery platforms allow us to look at cancer from every angle, targeting the cancer directly and the environment it lives in, and amplifying the body’s ability to fight disease. We are committed to reflecting diverse patient populations in our clinical trials, and are collaborating with partners across the healthcare landscape to increase the speed and efficiency of our research.
As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
Ferronova is an Australian biotechnology company commercialising magnetic nanoparticle and molecular imaging, that can be applied to a variety of medical applications. Their first-generation product is a combination device/drug system intended to aid in more accurate staging of solid tumour cancers. Ferronova’s mission is to ensure no cancer goes undetected. They aim to enable surgeons, oncologists and pathologists to maximise the use of their skills, support less invasive procedures and improve overall patient outcomes.
Ipsen provides specialty medicines to Healthcare Professionals and their patients suffering from debilitating diseases. At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. Ipsen is the Australian affiliate of a global R&D focused pharmaceutical company.
The Pierre Fabre Group, founded by a pharmacist Pierre Fabre, is the second largest private pharmaceutical company in France. Owned by a government recognised public interest foundation, the Group is committed to designing and developing innovative solutions to contribute to the wellbeing of everyone through products across consumer health, dermo-cosmetics and pharmaceuticals.
In Australia, Pierre Fabre has prescription medicines in the area of oncology, dermo-cosmetics brand Eau Thermale Avene (a skincare range for all forms of sensitive skin), and Klorane (a haircare range formulated from carefully selected botanical ingredients).
Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that’s committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development. Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. Servier Australia’s oncology products include Lonsurf® (trifluridine/tipiracil), Onivyde® (nanoliposomal irinotecan as sucrosofate) and Oncaspar
Specialised Therapeutics (ST) commercialises new therapies and technologies for patients in Australia, New Zealand and across South-East Asia. Our GI oncology portfolio includes ABRAXANE® (nanoparticle albumin-bound paclitaxel) for metastatic breast cancer and pancreatic cancer, QINLOCK® (ripretinib) for gastrointestinal stromal tumours and PEMAZYRE® (pemigatinib) for cholangiocarcinoma. The broader portfolio spans haematology, neurology, ophthalmology and supportive care.